Marché de la stimulation du nerf vague au Moyen-Orient et en Afrique – Tendances et prévisions de l’industrie jusqu’en 2029

Demande de table des matières Demande de table des matières Parler à un analysteParler à un analyste Acheter maintenantAcheter maintenant Renseignez-vous avant d'acheterRenseignez-vous avant Exemple de rapport gratuitExemple de rapport gratuit

Marché de la stimulation du nerf vague au Moyen-Orient et en Afrique – Tendances et prévisions de l’industrie jusqu’en 2029

  • Medical Devices
  • Publish Reports
  • Nov 2022
  • MEA
  • 350 Pages
  • Nombre de tableaux : 127
  • Nombre de figures : 44

Middle East And Africa Vagus Nerve Stimulation Market

Taille du marché en milliards USD

TCAC :  % Diagram

Diagram Période de prévision
2022 –2029
Diagram Taille du marché (année de référence)
USD 55.39 Million
Diagram Taille du marché (année de prévision)
USD 76.13 Million
Diagram TCAC
%
DiagramPrincipaux acteurs du marché
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5 < /li>

>Marché de la stimulation du nerf vague au Moyen-Orient et en Afrique, par type de produit (dispositifs VNS implantables et dispositifs VNS externes), biomatériaux (céramiques, métalliques et polymères), application (gestion de la douleur, crises d'épilepsie, gestion de l'obésité, dépression et anxiété, et autres), type de patient (adultes, pédiatriques et gériatriques), utilisateur final (hôpitaux, centres de chirurgie ambulatoire, centres spécialisés et autres), canal de distribution (appel d'offres direct, ventes au détail et autres) tendances et prévisions de l'industrie jusqu'en 2029.

Marché de la stimulation du nerf vague au Moyen-Orient et en Afrique

Analyse et perspectives du marché de la stimulation du nerf vague au Moyen-Orient et en Afrique

Le nerf vague est un élément important du système nerveux autonome qui régule l'homéostasie métabolique et fonctionne comme un élément essentiel de l'axe neuroendocrinien-immunitaire dans le maintien de l'homéostasie via ses voies afférentes et efférentes. Toute approche qui stimule le nerf vague, y compris la stimulation manuelle ou électrique, est appelée stimulation du nerf vague (SNV). Pour l'épilepsie réfractaire et la dépression résistante au traitement, la SNV cervicale gauche est une thérapie approuvée.

Marché de la stimulation du nerf vague au Moyen-Orient et en Afrique

Marché de la stimulation du nerf vague au Moyen-Orient et en Afrique

Selon l'OMS, les maladies neurologiques sont responsables de 4,5 à 11 % de toutes les maladies dans le monde. Les stimulateurs du nerf vague sont également utilisés pour traiter les patients souffrant d'épilepsie, de dépression, d'asthme et de troubles cardiovasculaires.

Le marché de la stimulation du nerf vague au Moyen-Orient et en Afrique devrait croître au cours de la période de prévision de 2022 à 2029. Data Bridge Market Research analyse que le marché croît avec un TCAC de 4,1% au cours de la période de prévision de 2022 à 2029 et devrait atteindre 76,13 millions USD d'ici 2029 contre 55,39 millions USD en 2021.

Rapport métrique

Détails

Période de prévision

2022 à 2029

Année de base

2021

Année historique

2020 (personnalisable de 2019 à 2014)

Unités quantitatives

Chiffre d'affaires en millions USD

Segments couverts

Par type de produit (dispositifs VNS implantables et dispositifs VNS externes), biomatériaux ( céramiques , métalliques et polymères), application (gestion de la douleur, crises d'épilepsie, gestion de l'obésité, dépression et anxiété, et autres), type de patient (adultes, pédiatriques et gériatriques), utilisateur final (hôpitaux, centres de chirurgie ambulatoire , centres spécialisés et autres).

Pays couverts

Afrique du Sud, Émirats arabes unis, Égypte, Arabie saoudite, Israël et reste du Moyen-Orient et de l'Afrique

Acteurs du marché couverts

Medtronic, LivaNova PLC, electroCore, Inc., Soterix Medical Inc., SetPoint Medical, MicroTransponder Inc, Parasym Ltd et tVNS Technologies GmbH entre autres.

Définition du marché : Marché de la stimulation du nerf vague au Moyen-Orient et en Afrique

The vagus nerve is a long cranial nerve that runs from a person’s brain stem into the neck, chest, and abdomen. It is a part of the parasympathetic nervous system, which is commonly referred to as the rest-and-digest system because it regulates body functions while a person is at rest. It delivers messages to a person’s brain from their digestive system and organs such as their lungs, heart, and liver. It controls several organ functions, including digestion, heart rate, and respiratory rate. It is responsible for vasomotor activity and reflexes. It also regulates vocalization, mood, and immunity. It influences sensory functions in a person’s ears, sinuses, and esophagus as well.

VNS involves a pulse generator inserted under a person’s skin on their chest. The implantable device, which is similar to a pacemaker, delivers regular electrical pulses to the brain via the vagus nerve. It is possible to provide additional stimulation by placing the provided magnet over the pulse generator. Relaxation techniques such as breathing exercises, yoga, and medication can influence vagus nerve activity, increasing its ability to relieve anxiety and mood-related symptoms. VNS can improve an individual’s physical health and can offer benefits for several conditions such as epilepsy and depression. The treatment has a healing effect on a person’s body due to its ability to promote relaxation and reduce inflammation.

Market Dynamics: Middle East and Africa Vagus Nerve Stimulation Market

Drivers

  • Increasing prevalence and incidence of neurological disorders

Neurological disorders cause 4.5% to 11% of all illnesses, whether in low or high-income countries. The impact is greater compared to that of malignancies, gastrointestinal diseases, or respiratory illnesses, and it is expected to grow over the next years. One of the most common neurological conditions, epilepsy, affects almost every country on earth. Most people with this illness are seen in high-population countries. Due to this rising prevalence, there is a rising demand for a variety of tools and treatments, such as VNS. More neurological problems are being treated with VNS. In addition to other clinical uses, it aids in the treatment of neurological conditions like epilepsy and depression due to the significant prevalence of neurological conditions worldwide.

  • Innovative non-invasive vagus nerve stimulation devices introduced to meet demand

Traditional and conventional VNS devices are implanted in the patient's body and leads are placed on the vagus nerves that provide electrical stimulation when required. Growing demand and technological advancement of innovative devices lead to the introduction of small-sized implantable VNS devices in the market. These small-sized implantable devices offer various clinical benefits to patients and healthcare providers. The introduction of innovative devices is anticipated to boost the market growth.

Constant focus by market players to innovate and launch new products had led to the emergence of non-invasive VNS (nVNS) devices in the market. These devices are also known as transcutaneous VNS (tVNS) devices

  • Rise in product approvals

The approval for VNS devices is governed by the U.S. FDA and the EU. The FDA issues a final protocol for filing a Pre-market Approval Application (PMA) or a notice of completion of a Product Development Protocol (PDP).

For instance,

  • The FDA has approved an implantable vagus nerve stimulator to treat epilepsy and depression. In addition, in Middle East and Africa, new nVNS devices that do not require surgical implantation to treat epilepsy, depression, and pain have been approved.

The approval received for VNS devices would result in the device being declared safe to use and ready for post-marketing approval. It would result in the supply and distribution of MRI machines to the developing markets, situated in the Middle East and Africa region. Hence, the rise in product approvals is expected to propel market growth.

  • Product development in recent years

Combination Therapies are much more effective than monotherapy, without additional side effects. They are a safe and effective alternative for individuals with refractory bladder conditions. Combining different target therapy strategies is the best approach to relieving patients of bladder disorders. Oral medication and behavioral therapy should be considered for the patients' refractory treatment. Various advanced target therapies are available such as sacral neuromodulation, intradetrusor injection of a botulinum toxin A, and percutaneous tibial nerve stimulation. These are advanced treatments and more effective as compared to oral agents.

Opportunities

  • Strategic initiatives by the key market players

The demand for VNS devices is increasing in the market owing to the increased levels of R&D; along with that, the market growth is being aided by the desire for innovative medications. Thus, the top market players have implemented new strategies by developing new devices and equipment as well as collaborating with other players in the market and aimed at improving business operations and profitability.

The companies operating Middle East and Africa in this market are adopting collaboration as a strategy to increase their product portfolio with advanced technology-rich products to boost their business in various dimensions. Thus, increasing strategic initiatives by key market players are expected to offer significant opportunities for market players operating in the market

  • Rising government initiatives for neurological disease

The purpose of funding for VNS devices is to encourage applications seeking to develop devices for various neurological disorders. Novel devices should move beyond existing electrical or magnetic stimulation and develop new stimulation techniques capable of increased spatiotemporal precision as well as multi-focal, closed-loop approaches. Therefore, the funding by the government would result in the safety of the patient and cost savings. In addition, hospitals and healthcare agencies would administer this treatment at a lower price through collaboration with government organizations. Hence, the advancements in R&D activities and funding by the government will act as an opportunity for this market growth.

Restraint/Challenge

  • High maintenance and device costs to restrain adoption of vagus nerve stimulators

The rise in the cost of VNS devices is due to technological development and increased demand for nVNS devices by neurologists in hospitals, clinics, nursing facilities, and ambulatory surgical centers. Overhead costs can help explain why hospitals charge so much for stimulation devices. The increased intricacy and cost of VNS devices, technological innovations, and robust investments would increase the costs. The increased cost would result in delayed treatment of patients in hospitals and clinics. Hence, the increased cost of VNS devices is expected to restrain market growth.

Post-COVID-19 Impact on Middle East and Africa Vagus Nerve Stimulation Market

The COVID-19 outbreak had a drastic effect on Middle East and Africa healthcare with a number of countries severely impacted. The pandemic had a negative impact on the market growth, on account of a temporary halt in research activities in this field, coupled with the low influx of patients in hospitals and diagnostic centers.

Manufacturers are making various strategic decisions to bounce back post-COVID-19. The players are conducting multiple R&D activities, product launches, and strategic partnerships to improve the technology and test results involved in the pharmacogenetics testing market.

Recent Development

  • In May 2022, electroCore, Inc. announced that the gammaCore Sapphire non-invasive Vagus Nerve Stimulator will be available in 130 National Spine and Pain Centers (NSPC) affiliated locations across the U.S. for patients suffering from pain associated with different forms of primary headache. This would help the organization to develop more revenue.

Middle East and Africa Vagus Nerve Stimulation Market Scope

Middle East and Africa vagus nerve stimulation market is segmented into product type, biomaterial, application, patient type, end user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.

Product Type

  • Implantable VNS Devices
  • External VNS Devices

En fonction du type de produit, le marché est segmenté en dispositifs VNS implantables et dispositifs VNS externes.

Biomatériau

  • Céramique
  • Métallique
  • Polymère

Basé sur les biomatériaux, le marché est segmenté en céramiques, métalliques et polymères.

Application

  • Gestion de la douleur
  • Crises d'épilepsie
  • Gestion de l'obésité
  • Dépression et anxiété
  • Autres

En fonction des applications, le marché est segmenté en gestion de la douleur, crises d’épilepsie, gestion de l’obésité, dépression et anxiété, et autres.

Type de patient

  • Adultes
  • Pédiatrique
  • Gériatrie

En fonction du type de patient, le marché est segmenté en adultes, pédiatriques et gériatriques.

Utilisateur final

  • Hôpital
  • Centres de chirurgie ambulatoire
  • Centres spécialisés
  • Autres

En fonction de l’utilisateur final, le marché est segmenté en hôpitaux, centres de chirurgie ambulatoire, centres spécialisés et autres.

Canal de distribution

  • Appel d'offres direct
  • Ventes au détail
  • Autres

En fonction du canal de distribution, le marché est segmenté en appels d'offres directs, ventes au détail et autres.

Analyse/perspectives régionales du marché de la stimulation du nerf vague au Moyen-Orient et en Afrique 

Le marché de la stimulation du nerf vague au Moyen-Orient et en Afrique est analysé et des informations et tendances sur la taille du marché sont fournies par pays, type de produit, biomatériau, application, type de patient, utilisateur final et canal de distribution comme référencé ci-dessus.

L'Afrique du Sud domine le marché de la stimulation du nerf vague au Moyen-Orient et en Afrique en termes de part de marché et de chiffre d'affaires et continuera de renforcer sa domination au cours de la période de prévision. Cela est dû à la prévalence et à l'incidence élevées des troubles neurologiques dans la région, et les investissements croissants en R&D et le lancement de nouveaux produits stimulent la croissance du marché.

La section pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements de réglementation sur le marché qui ont un impact sur les tendances actuelles et futures du marché. Les points de données, tels que les ventes de produits neufs et de remplacement, la démographie des pays, l'épidémiologie des maladies et les tarifs d'importation et d'exportation, sont quelques-uns des principaux indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques du Moyen-Orient et d'Afrique et les défis auxquels elles sont confrontées en raison de la concurrence des marques locales et nationales et l'impact des canaux de vente sont pris en compte tout en fournissant une analyse prévisionnelle des données nationales.

Analyse du paysage concurrentiel et des parts de marché de la stimulation du nerf vague au Moyen-Orient et en Afrique

Le paysage concurrentiel du marché de la stimulation du nerf vague au Moyen-Orient et en Afrique fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements en R&D, les nouvelles initiatives du marché, la présence au Moyen-Orient et en Afrique, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit et la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises par rapport au marché.

Certains des principaux acteurs opérant sur le marché sont Medtronic, LivaNova PLC, electroCore, Inc., Soterix Medical Inc., SetPoint Medical, MicroTransponder Inc, Parasym Ltd et tVNS Technologies GmbH, entre autres.

Méthodologie de recherche

La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des tailles d'échantillon importantes. Les données du marché sont analysées et estimées à l'aide de modèles statistiques et cohérents du marché. En outre, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. La principale méthodologie de recherche utilisée par l'équipe de recherche DBMR est la triangulation des données, qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données comprennent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement de l'entreprise, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse MEA vs. régionale et la part des fournisseurs. Veuillez demander un appel d'analyste en cas de demande de renseignements supplémentaires.


SKU-

Accédez en ligne au rapport sur le premier cloud mondial de veille économique

  • Tableau de bord d'analyse de données interactif
  • Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
  • Accès d'analyste de recherche pour la personnalisation et les requêtes
  • Analyse de la concurrence avec tableau de bord interactif
  • Dernières actualités, mises à jour et analyse des tendances
  • Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Demande de démonstration

Table des matières

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 LIFELINE CURVE , BY PRODUCT TYPE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET APPLICATION COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PORTER’S FIVE FORCES

4.2 PESTEL ANALYSIS

4.3 KEY STRATEGIC INITIATIVES

5 REGULATIONS OF MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 INCREASING PREVALENCE AND INCIDENCE OF NEUROLOGICAL DISORDERS

6.1.2 INNOVATIVE NON-INVASIVE VAGUS NERVE STIMULATION DEVICES INTRODUCED TO MEET DEMAND

6.1.3 RISE IN PRODUCT APPROVALS

6.1.4 PRODUCT DEVELOPMENT IN RECENT YEARS

6.2 RESTRAINTS

6.2.1 HIGH MAINTENANCE AND DEVICE COSTS TO RESTRAIN ADOPTION OF VAGUS NERVE STIMULATORS

6.2.2 RISE IN PRODUCT RECALL

6.2.3 UNFAVORABLE REIMBURSEMENT POLICIES

6.3 OPPORTUNITIES

6.3.1 STRATEGIC INITIATIVES BY KEY MARKET PLAYERS

6.3.2 RISING GOVERNMENT INITIATIVES FOR NEUROLOGICAL DISEASE

6.4 CHALLENGES

6.4.1 RISKS ASSOCIATED WITH THE IMPLANTATION OF THESE DEVICES

6.4.2 LACK OF SKILLED HEALTHCARE PROFESSIONALS

6.4.3 STRINGENT REGULATIONS FOR APPROVAL OF MEDICAL DEVICES

7 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE

7.1 OVERVIEW

7.2 IMPLANTABLE VNS DEVICE

7.3 EXTERNAL VNS DEVICE

8 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL

8.1 OVERVIEW

8.2 METALLIC

8.3 POLYMERIC

8.4 CERAMICS

9 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET, BY APPLICATION

9.1 OVERVIEW

9.2 EPILEPTIC SEIZURES

9.2.1 IMPLANTABLE VNS DEVICE

9.2.2 EXTERNAL VNS DEVICE

9.3 DEPRESSION AND ANXIETY

9.3.1 IMPLANTABLE VNS DEVICE

9.3.2 EXTERNAL VNS DEVICE

9.4 PAIN MANAGEMENT

9.4.1 IMPLANTABLE VNS DEVICE

9.4.2 EXTERNAL VNS DEVICE

9.5 OBESITY MANAGEMENT

9.5.1 IMPLANTABLE VNS DEVICE

9.5.2 EXTERNAL VNS DEVICE

9.6 OTHERS

10 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE

10.1 OVERVIEW

10.2 ADULTS

10.2.1 IMPLANTABLE VNS DEVICES

10.2.2 EXTERNAL VNS DEVICES

10.3 GERIATRIC

10.3.1 IMPLANTABLE VNS DEVICES

10.3.2 EXTERNAL VNS DEVICES

10.4 PEDIATRIC

10.4.1 IMPLANTABLE VNS DEVICES

10.4.2 EXTERNAL VNS DEVICES

11 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET, BY END USER

11.1 OVERVIEW

11.2 SPECIALTY CENTERS

11.3 HOSPITALS

11.4 AMBULATORY SURGICAL CENTERS (ASCS)

11.5 OTHERS

12 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL

12.1 OVERVIEW

12.2 DIRECT TENDER

12.3 RETAIL SALES

12.4 OTHERS

13 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET, BY REGION

13.1 MIDDLE EAST AND AFRICA

13.1.1 SOUTH AFRICA

13.1.2 UAE

13.1.3 EGYPT

13.1.4 SAUDI ARABIA

13.1.5 ISRAEL

13.1.6 REST OF MIDDLE EAST AND AFRICA

14 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: COMPANY LANDSCAPE

14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA

15 SWOT ANALYSIS

16 COMPANY PROFILE

16.1 ELECTROCORE, INC.

16.1.1 COMPANY SNAPSHOT

16.1.2 REVENUE ANALYSIS

16.1.3 COMPANY SHARE ANALYSIS

16.1.4 PRODUCT PORTFOLIO

16.1.5 RECENT DEVELOPMENTS

16.2 LIVANOVA PLC

16.2.1 COMPANY SNAPSHOT

16.2.2 REVENUE ANALYSIS

16.2.3 COMPANY SHARE ANALYSIS

16.2.4 PRODUCT PORTFOLIO

16.2.5 RECENT DEVELOPMENTS

16.3 MEDTRONIC

16.3.1 COMPANY SNAPSHOT

16.3.2 REVENUE ANALYSIS

16.3.3 COMPANY SHARE ANALYSIS

16.3.4 PRODUCT PORTFOLIO

16.3.5 RECENT DEVELOPMENTS

16.4 SETPOINT MEDICAL

16.4.1 COMPANY SNAPSHOT

16.4.2 COMPANY SHARE ANALYSIS

16.4.3 PRODUCT PORTFOLIO

16.4.4 RECENT DEVELOPMENTS

16.5 TVNS TECHNOLOGIES GMBH

16.5.1 COMPANY SNAPSHOT

16.5.2 COMPANY SHARE ANALYSIS

16.5.3 PRODUCT PORTFOLIO

16.5.4 RECENT DEVELOPMENT

16.6 NEUROPIX COMPANY LTD.

16.6.1 COMPANY SNAPSHOT

16.6.2 PRODUCT PORTFOLIO

16.6.3 RECENT DEVELOPMENT

16.7 BRAIN CONTROL CO. LTD

16.7.1 COMPANY SNAPSHOT

16.7.2 PRODUCT PORTFOLIO

16.7.3 RECENT DEVELOPMENTS

16.8 CIRTEC

16.8.1 COMPANY SNAPSHOT

16.8.2 PRODUCT PORTFOLIO

16.8.3 RECENT DEVELOPMENTS

16.9 MICROTRANSPONDER INC.

16.9.1 COMPANY SNAPSHOT

16.9.2 PRODUCT PORTFOLIO

16.9.3 RECENT DEVELOPMENT

16.1 PARASYM LTD

16.10.1 COMPANY SNAPSHOT

16.10.2 PRODUCT PORTFOLIO

16.10.3 RECENT DEVELOPMENT

16.11 RESHAPE LIFESCIENCES INC. (2021)

16.11.1 COMPANY SNAPSHOT

16.11.2 REVENUE ANALYSIS

16.11.3 PRODUCT PORTFOLIO

16.11.4 RECENT DEVELOPMENT

16.12 SOTERIX MEDICAL INC.

16.12.1 COMPANY SNAPSHOT

16.12.2 PRODUCT PORTFOLIO

16.12.3 RECENT DEVELOPMENTS

17 QUESTIONNAIRE

18 RELATED REPORTS

Liste des tableaux

TABLE 1 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 2 MIDDLE EAST & AFRICA IMPLANTABLE VNS DEVICES IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 3 MIDDLE EAST & AFRICA EXTERNAL VNS DEVICES IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 4 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)

TABLE 5 MIDDLE EAST & AFRICA METALLIC IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 6 MIDDLE EAST & AFRICA POLYMERIC IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 7 MIDDLE EAST & AFRICA CERAMICS IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 8 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 9 MIDDLE EAST & AFRICA EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 MIDDLE EAST & AFRICA EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 11 MIDDLE EAST & AFRICA DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 12 MIDDLE EAST & AFRICA DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 13 MIDDLE EAST & AFRICA PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 14 MIDDLE EAST & AFRICA PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 15 MIDDLE EAST & AFRICA OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 16 MIDDLE EAST & AFRICA OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 17 MIDDLE EAST & AFRICA OTHERS IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 18 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 19 MIDDLE EAST & AFRICA ADULTS IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 20 MIDDLE EAST & AFRICA ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 21 MIDDLE EAST & AFRICA GERIATRICS IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 22 MIDDLE EAST & AFRICA GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 23 MIDDLE EAST & AFRICA PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 24 MIDDLE EAST & AFRICA PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 25 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 26 MIDDLE EAST & AFRICA SPECIALTY CENTERS IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 27 MIDDLE EAST & AFRICA HOSPITALS IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 28 MIDDLE EAST & AFRICA AMBULATORY SURGICAL CENTERS (ASCS) IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 29 MIDDLE EAST & AFRICA OTHERS IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 30 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 31 MIDDLE EAST & AFRICA DIRECT TENDER IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 32 MIDDLE EAST & AFRICA RETAIL SALES IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 33 MIDDLE EAST & AFRICA OTHERS IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 34 MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 35 MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 36 MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)

TABLE 37 MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)

TABLE 38 MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)

TABLE 39 MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 40 MIDDLE EAST AND AFRICA EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 41 MIDDLE EAST AND AFRICA DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 42 MIDDLE EAST AND AFRICA PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 43 MIDDLE EAST AND AFRICA OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 44 MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 45 MIDDLE EAST AND AFRICA ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 46 MIDDLE EAST AND AFRICA GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 47 MIDDLE EAST AND AFRICA PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 48 MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 49 MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 50 SOUTH AFRICA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 51 SOUTH AFRICA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)

TABLE 52 SOUTH AFRICA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)

TABLE 53 SOUTH AFRICA VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)

TABLE 54 SOUTH AFRICA VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 55 SOUTH AFRICA EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 56 SOUTH AFRICA DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 57 SOUTH AFRICA PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 58 SOUTH AFRICA OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 59 SOUTH AFRICA VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 60 SOUTH AFRICA ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 61 SOUTH AFRICA GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 62 SOUTH AFRICA PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 63 SOUTH AFRICA VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 64 SOUTH AFRICA VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 65 UAE VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 66 UAE VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)

TABLE 67 UAE VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)

TABLE 68 UAE VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)

TABLE 69 UAE VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 70 UAE EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 71 UAE DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 72 UAE PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 73 UAE OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 74 UAE VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 75 UAE ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 76 UAE GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 77 UAE PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 78 UAE VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 79 UAE VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 80 EGYPT VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 81 EGYPT VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)

TABLE 82 EGYPT VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)

TABLE 83 EGYPT VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)

TABLE 84 EGYPT VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 85 EGYPT EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 86 EGYPT DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 87 EGYPT PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 88 EGYPT OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 89 EGYPT VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 90 EGYPT ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 91 EGYPT GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 92 EGYPT PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 93 EGYPT VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 94 EGYPT VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 95 SAUDI ARABIA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 96 SAUDI ARABIA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)

TABLE 97 SAUDI ARABIA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)

TABLE 98 SAUDI ARABIA VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)

TABLE 99 SAUDI ARABIA VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 100 SAUDI ARABIA EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 101 SAUDI ARABIA DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 102 SAUDI ARABIA PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 103 SAUDI ARABIA OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 104 SAUDI ARABIA VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 105 SAUDI ARABIA ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 106 SAUDI ARABIA GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 107 SAUDI ARABIA PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 108 SAUDI ARABIA VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 109 SAUDI ARABIA VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 110 ISRAEL VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 111 ISRAEL VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)

TABLE 112 ISRAEL VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)

TABLE 113 ISRAEL VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)

TABLE 114 ISRAEL VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 115 ISRAEL EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 116 ISRAEL DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 117 ISRAEL PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 118 ISRAEL OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 119 ISRAEL VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 120 ISRAEL ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 121 ISRAEL GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 122 ISRAEL PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 123 ISRAEL VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 124 ISRAEL VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 125 REST OF MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 126 REST OF MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)

TABLE 127 REST OF MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)

Liste des figures

FIGURE 1 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: DBMR MARKET POSITION GRID

FIGURE 8 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 9 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: SEGMENTATION

FIGURE 11 THE GROWING DEMAND FOR INNOVATIVE NON–INVASIVE VAGUS STIMULATION DEVICES AND THE INCREASED PREVALENCE OF NEUROLOGICAL DISORDERS ARE EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 IMPLANTABLE VNS DEVICE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET IN 2022 & 2029

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET

FIGURE 14 INCIDENCE OF ADULT-ONSET BRAIN DISORDERS IN THE U.S. IN 2021

FIGURE 15 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: BY PRODUCT TYPE, 2021

FIGURE 16 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: BY PRODUCT TYPE, 2022-2029 (USD MILLION)

FIGURE 17 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: BY PRODUCT TYPE, CAGR (2022-2029)

FIGURE 18 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: BY PRODUCT TYPE, LIFELINE CURVE

FIGURE 19 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: BY BIOMATERIAL, 2021

FIGURE 20 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: BY BIOMATERIAL, 2022-2029 (USD MILLION)

FIGURE 21 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: BY BIOMATERIAL, CAGR (2022-2029)

FIGURE 22 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: BY BIOMATERIAL, LIFELINE CURVE

FIGURE 23 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: BY APPLICATION, 2021

FIGURE 24 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: BY APPLICATION, 2022-2029 (USD MILLION)

FIGURE 25 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: BY APPLICATION, CAGR (2022-2029)

FIGURE 26 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 27 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: BY PATIENT TYPE, 2021

FIGURE 28 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: BY PATIENT TYPE, 2022-2029 (USD MILLION)

FIGURE 29 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: BY PATIENT TYPE, CAGR (2022-2029)

FIGURE 30 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: BY PATIENT TYPE, LIFELINE CURVE

FIGURE 31 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: BY END USER, 2021

FIGURE 32 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: BY END USER, 2022-2029 (USD MILLION)

FIGURE 33 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: BY END USER, CAGR (2022-2029)

FIGURE 34 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: BY END USER, LIFELINE CURVE

FIGURE 35 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: BY DISTRIBUTION CHANNEL, 2021

FIGURE 36 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)

FIGURE 37 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)

FIGURE 38 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 39 MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET: SNAPSHOT (2021)

FIGURE 40 MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET: BY COUNTRY (2021)

FIGURE 41 MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET: BY COUNTRY (2022 & 2029)

FIGURE 42 MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET: BY COUNTRY (2021 & 2029)

FIGURE 43 MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET: BY PRODUCT TYPE (2022 - 2029)

FIGURE 44 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: COMPANY SHARE 2021 (%)

Voir les informations détaillées Right Arrow

Méthodologie de recherche

La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.

La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.

Personnalisation disponible

Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.

Questions fréquemment posées

The Middle East and Africa Vagus Nerve Stimulation Market size will be worth USD 76.13 million by 2029.
The Middle East and Africa Vagus Nerve Stimulation Market growth rate will be 4.1% by 2029.
Innovative non-invasive vagus nerve stimulation devices introduced to meet demand and Increasing prevalence and incidence of neurological disorders are the growth drivers of the Middle East and Africa Vagus Nerve Stimulation Market.
The product type, biomaterial, application, patient type, end user, and distribution channel are the factors on which the Middle East and Africa Vagus Nerve Stimulation Market research is based.
The major companies in the Middle East and Africa Vagus Nerve Stimulation Market are Medtronic, LivaNova PLC, electroCore, Inc., Soterix Medical Inc., SetPoint Medical, MicroTransponder Inc, Parasym Ltd, and tVNS Technologies GmbH.